Cypress Capital Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cypress Capital Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,455	Closed	-$387K	–	343
2021 Q4	$387K	Sell	3,455 -9,078	-72%	-$1.09M	0.05%	232
2021 Q3	$1.58M	Sell	12,533 -681	-5%	-$87.7K	0.21%	105
2021 Q2	$1.79M	Buy	13,214 +1,319	+11%	+$173K	0.24%	97
2021 Q1	$1.61M	Buy	11,895 +4,682	+65%	+$701K	0.23%	102
2020 Q4	$1.01M	Buy	7,213 +4,293	+147%	+$550K	0.15%	120
2020 Q3	$325K	Buy	+2,920	New	+$327K	0.05%	212
2019 Q2	–	Sell	-2,339	Closed	-$212K	–	247
2019 Q1	$212K	Sell	2,339 -500	-18%	-$42.5K	0.04%	230
2018 Q4	$204K	Sell	2,839 -7,057	-71%	-$569K	0.05%	227
2018 Q3	$949K	Buy	9,896 +1,504	+18%	+$146K	0.18%	114
2018 Q2	$799K	Buy	+8,392	New	+$771K	0.16%	120

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Cypress Capital Group's XBI Position: Q1 2022 in Review

Cypress Capital Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 3,455 shares — an estimated $387K sold.

Cypress Capital Group first reported a position in XBI in Q2 2018 and held it in 10 quarters. The position peaked at $1.79M in Q2 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Cypress Capital Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Cypress Capital Group sold 3,455 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $387K.
Cypress Capital Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2018 and held it in 10 quarters.
Cypress Capital Group's State Street SPDR S&P Biotech ETF position peaked at $1.79M in Q2 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Cypress Capital Group's 13F filing for Q1 2022, filed 16 May 2022.